Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 8/20 | 0.43 |
| ▸ | GSK3A | P49840 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872745 | 0.83 | PIN1 (0.48) | KMT2AMEN1ALDH1A1PIN1GSK3A | |
| SCHEMBL30466223 | 0.77 | PIN1 (0.71) | ALDH1A1PIN1CYP2D6 | |
| SCHEMBL12673042 | 0.75 | ALDH1A1 (0.34) | ALDH1A1PIN1 | |
| SCHEMBL12627083 | 0.74 | KMT2A (0.48) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL13543074 | 0.74 | KMT2A (0.48) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL6618744 | 0.72 | KMT2A (0.49) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL15425987 | 0.71 | TSHR (0.51) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL7667955 | 0.70 | POLB (0.47) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL21538549 | 0.68 | OPRL1 (0.46) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL5935423 | 0.68 | OPRM1 (0.64) | KMT2AMEN1ALDH1A1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | KMT2A 4687/4885MEN1 1935/4885ALDH1A1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.